Prevalence and molecular characterization of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in Riyadh, Saudi Arabia

Annals of Saudi Medicine - Tập 29 Số 4 - Trang 253-257 - 2009
Mohamed H. Al-Agamy1, Atef M. Shibl1, A.F. Tawfik1
1From the College of Pharmacy, Pharmaceutics and Microbiology Department, King Saud University, Riyadh, Saudi Arabia

Tóm tắt

Từ khóa


Tài liệu tham khảo

Kiratisin P, 2008, Molecular characterization and epidemiology of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic, Antimicrob Agents Chemother, 52, 2818, 10.1128/AAC.00171-08

Bush K, 1995, A functional classification scheme for β-lactamases and its correlation with molecular structure, Antimicrob Agents Chemother, 39, 1211, 10.1128/AAC.39.6.1211

Paterson DL, 2005, Extended-spectrum β-lactamases: a clinical update, Clin Microbiol Rev, 18, 657, 10.1128/CMR.18.4.657-686.2005

Knothe H, 1983, Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of 1Klebsiella pneumoniae and Serratia marcescens, Infect, 11, 315, 10.1007/BF01641355

Bauernfeind A, 1990, A new plasmidic cefotaximase from patients infected with Salmonella typhimorium, Infect, 20, 158, 10.1007/BF01704610

Barthélémy M, 1992, Close amino acid sequence relationship between the new plasmid-mediated extended-spectrum β-lactamase MEN-1 and chromosomally encoded enzymes of Klebsiella oxytoca, Biochim Biophys Acta, 1122, 15, 10.1016/0167-4838(92)90121-S

Bonnet R, 2004, Growing Group of Extended-Spectrum β-Lactamases: the CTX-M Enzymes, Antimicrob Agents Chemother, 48, 1, 10.1128/AAC.48.1.1-14.2004

Paterson DL, 2003, Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type_-lactamases, Antimicrob Agents Chemother, 47, 3554, 10.1128/AAC.47.11.3554-3560.2003

Al-agamy MHM, 2006, First description of CTX-M β-lactamase-producing clinical Escherichia coli isolates from Egypt, Inter J Antimicrob Agents, 27, 545, 10.1016/j.ijantimicag.2006.01.007

Soge OO, 2006, CTX-M-15 extended-spectrum β-lactamases from Nigerian Klebsiella pneumoniae, J Antimicrob Chemother, 57, 24, 10.1093/jac/dki429

Livermore DM, 2007, CTX-M: changing the face of ESBLs in Europe, J Antimicrob Chemother, 59, 165, 10.1093/jac/dkl483

El-Khizzi NA, 2006, Prevalence of extended-spectrum beta-lactamases among Enterobacteriaceae isolated from blood culture in a tertiary care hospital, Saudi Med J, 27, 37

10.5144/0256-4947.2005.239

Panhotra BR, 2004, Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia Risk factors and clinical outcome, Saudi Med J, 25, 1871

Clinical and Laboratory Standards Institute, 2006, Approved standard M7-A7 CLSI, 7

Nüesch-Inderbinen MT, 1997, Survey and molecular genetics of SHV β-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12, Antimicrob Agents Chemother, 41, 943, 10.1128/AAC.41.5.943

Bonnet R, 2001, Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240_Gly, Antimicrob Agents Chemother, 45, 2269, 10.1128/AAC.45.8.2269-2275.2001

Baraniak A, 2002, Ceftazidime-hydrolyzing CTX-M-15 extended-spectrum beta-lactamase (ESBL) in Poland, J Antimicrob Chemother, 50, 393, 10.1093/jac/dkf151

Villegas MV, 2004, Prevalence and characterization of extended-spectrum beta-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals, Diagn Microbiol Infect Dis, 49, 217, 10.1016/j.diagmicrobio.2004.03.001

Chanawong A, 2002, Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China, Antimicrob Agents Chemother, 46, 630, 10.1128/AAC.46.3.630-637.2002

Bilal NE, 2001, Clinical and community strains of Klebsiella pneumoniae: multiple and increasing rates of antibiotic resistance in Abha, Saudi Arabia, Br J Biomed Sci, 57, 185

Goosens H, 2001, MYSTIC programme: summary of European data from 1997 to 2000, Diagn Microbiol Infect Dis, 41, 183, 10.1016/S0732-8893(01)00320-0

Otman J, 2002, An outbreak of extended-spectrum beta-lactamase-producing Klebsiella species in a neonatal intensive care unit in Brazil, Infect Control Hosp Epidemiol, 23, 8, 10.1086/503447

Pfaller MA, 1993, Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela: comparison of data from 1997 and 1998 using the E test method. Venezuelan Antimicrobial Resistance Study Group, Diagn Microbiol Infect Dis, 35, 153, 10.1016/S0732-8893(99)00071-1

Sader HS, 2000, Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98), Braz J Infect Dis, 4, 245

Lewis MT, 1999, In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group, Diagn Microbiol Infect Dis, 35, 307, 10.1016/S0732-8893(99)00120-0

Hawser SP, 2009, Emergence of High Levels of Extended-Spectrum {beta}-lactamase-producing Gram-negative Bacilli in Asia/Pacific: Data from SMART 2007, Antimicrob Agents Chemother

Shah AA, 2004, Prevalence of extended spectrum B-lactamases in nosocomial and outpatients (ambulatory), Pak J Med Sci, 19, 187

Jamal W, 2005, Prevalence of extended-spectrum beta-lactamases in Enterobacteriaceae, Pseudomonas and Stenotrophomonas as determined by the VITEK 2 and E test systems in a Kuwait teaching hospital, Med Princ Pract, 14, 325, 10.1159/000086930

Al-Zarouni M, 2008, Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates, Med Princ Pract, 17, 32, 10.1159/000109587

Shehabi AA, 2000, High incidence of Klebsiella pneumoniae clinical isolates to extended-spectrum β-lactam drugs in intensive care units, Diagn Microbiol Infect Dis, 36, 53, 10.1016/S0732-8893(99)00108-X

Goossens H, 2006, MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibility between countries and center types, J Antimicrob Chemother, 46, 39, 10.1093/jac/46.suppl_2.39

Andrews JM, 2001, BSAC working party on susceptibility testing: BSAC standardized susceptibility testing method, J Antimicrob Chemother, 48, 43, 10.1093/jac/48.suppl_1.43

Lautenbach E, 2001, Epidemiological investigation of fluoroquinolone resistance in infection due to extended-spectrum β-lactamases producing Escherichia coli and Klebsiella pneumoniae, Clin Infect Dis, 33, 1288, 10.1086/322667

Paterson DL, 2001, Rapid method of extraction and analysis of extended-spectrum β-lactamases from clinical strains of Klebsiella pneumoniae, Clin Microbiol Infect, 7, 709, 10.1046/j.1469-0691.2001.00363.x

Shahcheraghi F, 2007, Distribution of TEM and SHV beta-lactamase genes among Klebsiella pneumoniae strains isolated from patients in Tehran, Med Sci Monit, 13, BR247

Ensor VM, 2008, Predominance of CTX-M-15 extended spectrum beta-lactamases in diverse Escherichia coli and Klebsiella pneumoniae from hospital and community patients in Kuwait, Int J Antimicrob Agents, 33, 487, 10.1016/j.ijantimicag.2008.10.011

Sonnevend A, 2006, CTX-M-15-producing multidrug-resistant enteroaggregative Escherichia coli in the United Arab Emirates, Clin Microbiol Infect, 12, 582, 10.1111/j.1469-0691.2006.01413.x

Jemima SA, 2008, Multiplex PCR for bla(CTX-M) & bla(SHV) in the extended spectrum beta lactamase (ESBL) producing gram-negative isolates, Indian J Med Res, 128, 313